Display options
Cite
Phak JH, Kim HJ, Kim WC. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer. Prostate Int. 2015;4(1):25-9doi: 10.1016/j.prnil.2015.12.001.
Phak, J. H., Kim, H. J., & Kim, W. C. (2016). Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer. Prostate international, 4(1), 25-9. https://doi.org/10.1016/j.prnil.2015.12.001
Phak, Jeong Hoon, et al. "Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer." Prostate international vol. 4,1 (2016): 25-9. doi: https://doi.org/10.1016/j.prnil.2015.12.001
Phak JH, Kim HJ, Kim WC. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer. Prostate Int. 2016 Mar;4(1):25-9. doi: 10.1016/j.prnil.2015.12.001. Epub 2015 Dec 12. PMID: 27014661; PMCID: PMC4789329.
Copy Download .nbib Format: NLM
Share it on

Prostate Int. 2016 Mar;4(1):25-9. doi: 10.1016/j.prnil.2015.12.001. Epub 2015 Dec 12.

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.

Prostate international

Jeong Hoon Phak, Hun Jung Kim, Woo Chul Kim

Affiliations

  1. Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.

PMID: 27014661 PMCID: PMC4789329 DOI: 10.1016/j.prnil.2015.12.001

Abstract

BACKGROUND: Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. The purpose of this study was to compare the prostate-specific antigen (PSA) kinetics between conventionally fractionated external beam radiotherapy (CF-EBRT) and SBRT boost after whole pelvis EBRT (WP-EBRT) in localized prostate cancer.

METHODS: A total of 77 patients with localized prostate cancer [T-stage, T1-T3; Gleason score (GS) 5-9; PSA < 20 ng/mL] were enrolled. A total of 35 patients were treated with SBRT boost (21 Gy in 3 fractions) after WP-EBRT and 42 patients were treated with CF-EBRT (45 Gy WP-EBRT and boost of 25.2-30.6 Gy in 1.8-Gy fractions). PSA nadir and rate of change in PSA (slope) were calculated and compared.

RESULTS: With a median follow-up of 52.4 months (range, 14-74 months), the median PSA nadir and slope for SBRT boost were 0.29 ng/mL and -0.506, -0.235, -0.129, and -0.092 ng/mL/mo, respectively, for durations of 1 year, 2 years, 3 years, and 4 years postradiotherapy. Similarly, for CF-EBRT, the median PSA nadir and slopes were 0.39 ng/mL and -0.720 ng/mL/mo, -0.204 ng/mL/mo, -0.121 ng/mL/mo, and -0.067 ng/mL/mo, respectively. The slope of CF-EBRT was significantly different with a greater median rate of change for 1 year postradiotherapy than that of SBRT boost (P = 0.018). Contrastively, the slopes of SBRT boost for durations of 2 years, 3 years, and 4 years tended to be continuously greater than that of CF-EBRT. The significantly lower PSA nadir was observed in SBRT boost (median nadir 0.29 ng/mL) compared with CF-EBRT (median nadir 0.35 ng/mL, P = 0.025). Five-year biochemical failure (BCF) free survival was 94.3% for SBRT boost and 78.6% for CF-EBRT (P = 0.012).

CONCLUSION: Patients treated with SBRT boost after WP-EBRT experienced a lower PSA nadir and there tended to be a continuously greater rate of decline of PSA for durations of 2 years, 3 years, and 4 years than with CF-EBRT. The improved PSA kinetics of SBRT boost over CF-EBRT led to favorable BCF free survival.

Keywords: Cyberknife; PSA kinetics; PSA nadir; Prostate cancer; Stereotactic body radiotherapy

References

  1. Radiat Oncol. 2013 May 13;8:118 - PubMed
  2. Technol Cancer Res Treat. 2010 Oct;9(5):453-62 - PubMed
  3. Cancer. 1993 Aug 1;72(3):832-42 - PubMed
  4. JAMA. 2011 Dec 21;306(23):2549-51 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):20-4 - PubMed
  7. Radiother Oncol. 2013 May;107(2):129-33 - PubMed
  8. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1093-104 - PubMed
  10. Cancer Res Treat. 2015 Apr;47(2):127-41 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 - PubMed
  12. Radiother Oncol. 1997 Sep;44(3):213-21 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):677-85 - PubMed
  14. JAMA. 1999 May 5;281(17):1598-604 - PubMed
  15. Acta Oncol. 2015 Jun;54(6):832-8 - PubMed
  16. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):385-91 - PubMed
  17. Cancer. 1991 Jul 15;68(2):400-5 - PubMed
  18. Radiother Oncol. 1996 Aug;40(2):159-62 - PubMed
  19. Cancer. 1998 Jul 1;83(1):130-4 - PubMed
  20. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):512-7 - PubMed
  21. J Urol. 1996 Aug;156(2 Pt 1):450-3 - PubMed
  22. Front Oncol. 2014 Oct 31;4:278 - PubMed
  23. Radiat Oncol. 2014 Feb 02;9:42 - PubMed
  24. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  25. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 - PubMed
  26. Urology. 2004 Jan;63(1):110-3 - PubMed
  27. JAMA. 2012 Apr 18;307(15):1611-20 - PubMed
  28. J Clin Oncol. 1994 Jul;12(7):1402-7 - PubMed
  29. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34 - PubMed
  30. J Urol. 2006 Oct;176(4 Pt 1):1415-9 - PubMed
  31. J Clin Oncol. 1992 Aug;10(8):1208-17 - PubMed

Publication Types